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Over 15 years ago, the syndrome of Familial Isolated Pituitary Adenomas (FIPA) was defined 
in Liege as a familial association of pituitary adenomas arising in the absence of other clinical signs of 
hereditary syndromes such as multiple endocrine neoplasia type 1 or Carney complex. All types of 
secretory adenomas can occur in this context and FIPA families can either be homogenous (the same 
secretory type of adenoma in all affected members) or heterogenous. It was later found that 
mutations in the AIP (Aryl hydrocarbon receptor Interacting Protein) gene were responsible for 15-
20% of FIPA cases, with GH-secreting adenomas being well represented in the AIP-mutated group. 
Acromegalic patients that are AIP-mutated have a particularly severe phenotype with early disease 
onset, invasive adenomas, poor response to somatostatin analogues and need for multiple treatment 
courses. 
Recently, a new type of FIPA has been discovered, in the context of a novel pituitary disease 
called X-linked acro-gigantism (X-LAG). This disease causes early-onset gigantism due to massive GH 
hypersecretion. Children affected start accelerating their growth rate before the age of 3, reaching 
what are most likely the tallest heights reported in history. These children present some acromegalic 
features (acral enlargement and coarse facial traits) and biologically, prolactin hypersecretion is 
associated. The cause of this syndrome is a microduplication of a region on the X chromosome 
containing 4 genes, out of which GPR101 is most probably the one responsible for the phenotype. 
Activating mutations of this gene were also found in sporadic acromegaly cases. This discovery 
represents a new cause of gigantism and FIPA, due to a novel genetic mechanism in pituitary 
pathophysiology. It unveils new regulatory pathways of the growth hormone axis and could help 
identify targets for novel treatment possibilities in growth-hormone related diseases. 
